iBio
NASDAQ: IBIOSan Diego, US · Founded 2008 · Delaware corporation · 59 employees on LinkedIn
Find your way into iBio
824 people in our graph share verified history with the iBio team — schools, employers, funds. One of them is your warm intro.
Rolanda Fuunlockedknows Terence Ryan · together at Massachusetts Institute of Technology (overlapped)
×2knows the team · via Massachusetts Institute of Technology
×2knows the team · via GlaxoSmithKline
knows the team · via University of Miami
×2knows the team · via United States Air Force
knows the team · via Ulm University
iBio is a biopharmaceutical company with leadership experienced in drug discovery, development, and clinical operations across multiple therapeutic areas. The company appears to focus on innovative therapeutics and biologics development.
Founders & leadership
FD
Felipe DuraninChief Financial OfficerFelipe Duran is an executive officer at iBio with extensive experience in financial strategy and operations within biopharmaceutical organizations, including SEC reporting, capital raising, and strategic planning across global markets.
MB
Marc BanjakinChief Legal OfficerHe has extensive experience in legal operations across medical device and pharmaceutical sectors, with expertise in contract negotiation and regulatory compliance.
MA
Martin A. BrennerinCEO & CSOMartin A. Brenner is Chief Executive Officer and Chief Scientific Officer of iBio, a biopharmaceutical company focused on antibody therapeutics for obesity and cardiometabolic disease. He has held leadership roles in drug discovery and development at Merck, AstraZeneca, Eli Lilly, Pfizer, and Pfenex, and has expertise in multiple therapeutic modalities including antibodies, peptides, small molecules, oligonucleotides, and mRNA.
TR
Terence RyaninChief Scientific Officer2010–2019Chief Scientific Officer of iBio, Terence Ryan has experience managing cross-functional teams in drug discovery, with expertise spanning biomarker identification, systems biology, recombinant protein production, and the integration of omics technologies and machine learning in translational research.
RK
Robert KayExecutive Chairman and Chief Executive Officer
MG
Mark GiannoneChief Financial Officer
RE
Robert ErwinPresident
MC
Mr. Clark
AP
António ParadainExecutive
MB
Mr. Banjak
DB
Dr. Brenner
MB
Martin BrennerinCEO & CSOMartin Brenner is Chief Executive Officer and Chief Scientific Officer of iBio, a biopharmaceutical company focused on antibody therapeutics for obesity and cardiometabolic disease. He previously held leadership roles at Merck, AstraZeneca, Eli Lilly, Pfizer, and Pfenex, with expertise in drug discovery, development, and translational science across multiple therapeutic modalities.
Reported raises · per SEC filings
Form D private placements$54.3M disclosed across 4 of 8 rounds · 1900–2026
▶$26MraisedJan 2026 · 7 investors · BiotechnologyRule 506(b)
▶$26MraisedJan 2026 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David ArkowitzDirector
- William ClarkDirector
- Martin A. BrennerExecutive Officer, Director
- Antonio ParadaDirector
- Marc BanjakExecutive Officer
- Evert ShimmelpenninkDirector
- Felipe DuranExecutive Officer
- Alexandra KropotovaDirector
- Gary SenderDirector
- Offering amount
- $26M
- Amount sold
- $26M
- Sales commissions
- $1.6M
- Placement agents
- Oppenheimer & Co. Inc., LifeSci Capital LLC, Leerink Partners LLC
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.1MraisedMay 2025 · 5 investors · BiotechnologyRule 506(b)
▶$11.1MraisedMay 2025 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Felipe DuranExecutive Officer
- Marc BanjakExecutive Officer
- Alexandra KroptovaDirector
- Gary SenderDirector
- David ArkowitzDirector
- Martin A. BrennerExecutive Officer, Director
- William ClarkDirector
- Antonio ParadaDirector
- Evert ShimmelpenninkDirector
- Offering amount
- $11.1M
- Amount sold
- $11.1M
- Sales commissions
- $217K
- Placement agents
- Chardan Capital Markets LLC
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15.1MraisedApr 2024 · 8 investors · BiotechnologyRule 506(b)
▶$15.1MraisedApr 2024 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Felipe DuranExecutive Officer
- Gary SendeDirector
- William ClarkDirector
- Martin BrennerExecutive Officer
- Linda ArmstrongDirector
- James HillDirector
- Evert ShimmelpenninkDirector
- Alexandra KropotovaDirector
- Offering amount
- $15.1M
- Amount sold
- $15.1M
- Sales commissions
- $794.1K
- Placement agents
- Chardan Capital Markets LLC
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MofferedAug 2023 · 1 investors · BiotechnologyRule 506(b)
▶$10MofferedAug 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Marc BanjakExecutive Officer
- Gary SenderDirector
- Martin BrennerExecutive Officer
- Linda ArmstrongDirector
- James HillDirector
- Alexandra KropotovaDirector
- Evert SchimmelpenninkDirector
- William ClarkDirector
- Felipe DuranExecutive Officer
- Offering amount
- $10M
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.2MraisedFeb 2016 · 1 investors · BiotechnologyRule 506(b)
▶$2.2MraisedFeb 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Terence RyanExecutive Officer
- Robert KayExecutive Officer
- Mark GiannoneExecutive Officer
- Arthur ElliottDirector
- Glenn ChangDirector
- James HillDirector
- Philip RussellDirector
- John McKeyDirector
- Robert ErwinExecutive Officer
- Seymour FlugDirector
- Offering amount
- $2.2M
- Amount sold
- $2.2M
- First sale
- Jan 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
Robinhood65 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking Alpha60 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
StockTwits53 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
bio51 shared keywordsBIO is the world's largest advocacy association representing biotechnology companies and research institutions across the United States and 30+ other nations. The organization facilitates industry networking through events, conferences, and partnering software while providing cost-savings programs and advocacy services for member companies.
IO Biotech47 shared keywordsIOBiotech appears to be a biotech company focused on oncology, with a founder who has extensive experience in cancer drug development and clinical advancement from roles at Roche, Eli Lilly, and leading academic cancer centers.
Companies competing with iBio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does iBio do?
- iBio is a biopharmaceutical company with leadership experienced in drug discovery, development, and clinical operations across multiple therapeutic areas. The company appears to focus on innovative therapeutics and biologics development.
- How much funding has iBio raised?
- iBio has disclosed $54.3M raised across 4 of its 8 known rounds.
- Where is iBio headquartered?
- iBio is headquartered in San Diego, US.